GlassScriptPhysician profile
Amir Iqbal
NPI 1922236017
$2,088.51
in general payments reported to CMS, 2019-2025
33 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,390 · 2020: $221 · 2021: $67.11 · 2023: $139 · 2024: $160 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $310 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $310.26 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $325.85 | 2019-2024 | Xtandi |
| Genentech USA, INC. | $225.21 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $179.59 | 2019-2024 | Opdivo |
| Merck Sharp & Dohme LLC | $138.02 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $127.89 | 2019-2025 | |
| Incyte Corporation | $112.93 | 2019-2023 | |
| Amgen INC. | $65.33 | 2019-2023 | Kyprolis |
| Genzyme Corporation | $60.38 | 2019-2020 | |
| Daiichi Sankyo INC. | $59.06 | 2019-2024 | Enhertu |
| Exelixis INC. | $57.95 | 2019 | |
| Lilly USA, LLC | $56.46 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $53.61 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $51.35 | 2019-2024 | Onivyde |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.17 | 2019-2025 | |
| Abbott Laboratories | $43.62 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $41.18 | 2019-2020 | |
| Glaxosmithkline, LLC. | $40.62 | 2019-2025 | Blenrep |
| Pfizer INC. | $38.18 | 2019 | |
| Celgene Corporation | $37.87 | 2019 | |
| Kyowa Kirin, INC. | $32.16 | 2019 | |
| Eisai INC. | $31.78 | 2019 | |
| Taiho Oncology, INC. | $30.73 | 2019 | |
| Janssen Pharmaceuticals, INC | $30.63 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $30.00 | 2025 | |
| Tempus Ai, INC | $29.74 | 2025 | Xt Cdx |
| Abbvie INC. | $26.30 | 2024 | |
| Pharmacosmos Therapeutics INC. | $26.15 | 2024 | Monoferric |
| Genmab U.S., INC. | $19.37 | 2024 | Epkinly |
| Mylan Institutional INC. | $18.06 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.42 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $12.22 | 2019 | |
| Epizyme, INC. | $11.50 | 2021 | |
| Seagen INC. | $11.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.